About
Benjamin Sale is a data scientist specialising in the analysis of large-scale clinical, biological, and other research datasets, with expertise in managing secure data integration pipelines from diverse sources. His experience encompasses clinical trial design, management, and analysis, alongside quality management, and a strong background in Good Clinical Practice (GCP) and data security governance. He began his career in 2012 as a laboratory technician at DSTL Porton Down, earning an HNC in Natural Sciences and an NVQ in Laboratory Activities. In 2017, he graduated with a BSc in Biochemistry from the University of Bath and joined the Southampton Clinical Trials Unit (SCTU) within the Pharmacovigilance and Quality Team.
In 2019, Ben was awarded an NIHR pre-doctoral fellowship to develop his bioinformatics expertise, completing an MSc in Genomic Medicine from the University of Southampton. His bioinformatics work at SCTU, focused on the Lymphoma portfolio, provided a strong foundation in B cell malignancies. This expertise led to a role in the Forconi Cancer B Cell Group, where he supported the development of an early cancer diagnostic and research platform under the CRUK accelerator award, ECRIN-M3.
Recognising his contributions, Ben received an award from the Cancer Immunology Talent Fund to support the development of a user-friendly suite of bioinformatics tools (IgSeqR), aiming to become a key resource for immunology research.
Currently, Ben works within the Clinical Informatics Research Unit (CIRU) as part of the AXIS team. His work focuses on developing computational tools and methodologies to enhance data collection, analysis, and accessibility. He is involved in various projects across the AXIS portfolio, collaborating with members of University Hospital Southampton, the Southampton Biomedical Research Centre, the Southampton Emerging Therapies and Technologies Centre, and other national and international commercial partners. In his current role he maintains active involvement in the ECRIN-M3 consortium and research projects within the Cancer B Cell Group and supports the administration and development of the Wessex Sub National Secure Data Environment.